OncoMatch/Clinical Trials/NCT06207305
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
Is NCT06207305 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Dexamethasone and Famotidine for metastatic appendiceal adenocarcinoma.
Treatment: Dexamethasone · Diphenhydramine · Famotidine · Paclitaxel — To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
leukocytes ≥3000/mcl, absolute neutrophil count ≥1,500/mcl, platelets ≥75,000/mcl
Kidney function
creatinine ≤ 1.5x institutional uln
Liver function
total bilirubin ≤ institutional upper limit of normal (uln)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify